Updates are available Correction dated 2021-05-03
Click to view Correction: https://doi.org/10.1038/s41409-021-01316-8
-
Authors
Sharma, Akshay https://orcid.org/0000-0003-3281-2081
Badawy, Sherif M.
Suelzer, Elizabeth M. https://orcid.org/0000-0002-1809-8080
Murthy, Hemant S.
Prasad, Pinki
Eissa, Hesham
Carpenter, Paul A.
Hamadani, Mehdi https://orcid.org/0000-0001-5372-510X
Labopin, Myriam https://orcid.org/0000-0003-4514-4748
Schoemans, Hélène https://orcid.org/0000-0002-7568-8239
Tichelli, André
Phelan, Rachel
Hamilton, Betty K. https://orcid.org/0000-0003-1252-6539
Buchbinder, David
Im, Annie
Hunter, Rebecca
Brazauskas, Ruta
Burns, Linda J. https://orcid.org/0000-0003-1341-4424
- License Information
-
More Information
Article History
Received: 3 December 2020
Revised: 8 December 2020
Accepted: 10 December 2020
First Online: 29 January 2021
Change Date: 3 May 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41409-021-01316-8
Compliance with ethical standards
:
: AS is a paid consultant for Spotlight Therapeutics and CRISPR Therapeutics/Vertex Pharmaceuticals and Novartis. Between 2017 and 2020, Hélène Schoemans has participated in advisory boards for Incyte (2018) and Janssen & Novartis (2020). She has received speaker’s fees from Jazz Pharmaceuticals (2017); Novartis & Incyte (2018) and Incyte, Jazz Pharmaceuticals & Takeda (2019). She has received travel grants from EBMT (2017); EBMT, Celgene & Abbvie (2018); EBMT & Incyte (2019) and EBMT & Gilead (2020). Research funding was also received from Novartis for an investigator-initiated study and consultancy (2020). None of the other authors has a financial disclosure to make.
